[Clinical evaluation of the tumor marker CA125 in ovarian tumor (a cooperative study among 8 institutions)]. 1985

T Kato, and H Nishimura, and J Hamai, and T Yamabe, and H Nakajima, and T Nakano, and K Noda, and K Teshima, and H Suzuki, and G Ueda

UI MeSH Term Description Entries
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D002288 Adenocarcinoma, Mucinous An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed) Carcinoma, Colloid,Carcinoma, Mucinous,Adenocarcinomas, Mucinous,Carcinomas, Colloid,Carcinomas, Mucinous,Colloid Carcinoma,Colloid Carcinomas,Mucinous Adenocarcinoma,Mucinous Adenocarcinomas,Mucinous Carcinoma,Mucinous Carcinomas
D003536 Cystadenocarcinoma A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed) Cystadenocarcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D015295 Antigens, Tumor-Associated, Carbohydrate Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies. Antigens, Carbohydrate, Tumor-Associated,CA Antigens,Cancer-Associated Carbohydrate Antigens,Carbohydrate Antigens, Tumor-Associated,Tumor-Associated Carbohydrate Antigens,Antigen, Carcinoma-Associated,CA Antigen,CA(Oxford) Antigen,Carcinoma-Associated Antigen,Epitectin,Antigen, CA,Antigen, Carcinoma Associated,Antigens, CA,Antigens, Cancer-Associated Carbohydrate,Antigens, Tumor-Associated Carbohydrate,Cancer Associated Carbohydrate Antigens,Carbohydrate Antigens, Cancer-Associated,Carbohydrate Antigens, Tumor Associated,Carcinoma Associated Antigen,Tumor Associated Carbohydrate Antigens

Related Publications

T Kato, and H Nishimura, and J Hamai, and T Yamabe, and H Nakajima, and T Nakano, and K Noda, and K Teshima, and H Suzuki, and G Ueda
June 1986, Nihon Sanka Fujinka Gakkai zasshi,
T Kato, and H Nishimura, and J Hamai, and T Yamabe, and H Nakajima, and T Nakano, and K Noda, and K Teshima, and H Suzuki, and G Ueda
June 1986, Nihon Sanka Fujinka Gakkai zasshi,
T Kato, and H Nishimura, and J Hamai, and T Yamabe, and H Nakajima, and T Nakano, and K Noda, and K Teshima, and H Suzuki, and G Ueda
February 1990, Nihon rinsho. Japanese journal of clinical medicine,
T Kato, and H Nishimura, and J Hamai, and T Yamabe, and H Nakajima, and T Nakano, and K Noda, and K Teshima, and H Suzuki, and G Ueda
October 2004, Acta biochimica et biophysica Sinica,
T Kato, and H Nishimura, and J Hamai, and T Yamabe, and H Nakajima, and T Nakano, and K Noda, and K Teshima, and H Suzuki, and G Ueda
March 2015, Journal of ovarian research,
T Kato, and H Nishimura, and J Hamai, and T Yamabe, and H Nakajima, and T Nakano, and K Noda, and K Teshima, and H Suzuki, and G Ueda
August 2003, The Journal of biological chemistry,
T Kato, and H Nishimura, and J Hamai, and T Yamabe, and H Nakajima, and T Nakano, and K Noda, and K Teshima, and H Suzuki, and G Ueda
December 1989, Nihon Sanka Fujinka Gakkai zasshi,
T Kato, and H Nishimura, and J Hamai, and T Yamabe, and H Nakajima, and T Nakano, and K Noda, and K Teshima, and H Suzuki, and G Ueda
June 1999, Collegium antropologicum,
T Kato, and H Nishimura, and J Hamai, and T Yamabe, and H Nakajima, and T Nakano, and K Noda, and K Teshima, and H Suzuki, and G Ueda
December 2005, Gynecologic oncology,
T Kato, and H Nishimura, and J Hamai, and T Yamabe, and H Nakajima, and T Nakano, and K Noda, and K Teshima, and H Suzuki, and G Ueda
January 2020, Caspian journal of internal medicine,
Copied contents to your clipboard!